Skip to main content
Erschienen in: PharmacoEconomics 5/2008

01.05.2008 | Review Article

Economic Evaluation of Interventions to Treat Opiate Dependence

A Review of the Evidence

verfasst von: Dr Christopher M. Doran

Erschienen in: PharmacoEconomics | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Opiate dependence imposes a significant economic burden on society in terms of treatment-related costs and prevention services, other healthcare costs, the work absenteeism of patients, productivity loss arising from premature death of patients, costs associated with crime, and social welfare expenditure.
The objective of this research is to review the literature on economic evaluation of treatment of opiate dependence (including detoxification, maintenance and psychosocial support).
A literature review was performed on several electronic databases, including MEDLINE (Ovid), Cochrane Database of Systematic Reviews, NHS Economic Evaluation Library Database (via Cochrane Library), Web of Science, Social Science Citations Index, EMBASE and PsycINFO. A sensitive approach was used in order to maximize the number of articles retrieved; no language or publication year limitations were applied to the searches. A combination of subject heading term searches and natural word searches were used. The Drummond checklist was applied to assess the quality of economic evaluations.
A total of 259 articles were considered relevant, with eight review studies identified. The treatment spectrum ranged from detoxification to maintenance treatments involving the use of agonist and/or antagonist treatments. The evidence suggests that, although the quality of economic evaluations is reasonably good, there is a dearth of knowledge about the cost effectiveness of treatments for opiate dependence. The majority of the literature reporting the results of cost-effectiveness analyses used surrogate outcome measures and adopted a narrow treatment provider perspective. Studies that have conducted cost-benefit analyses, in spite of methodological divergences, generally adopted a societal perspective and consistently demonstrated positive economic returns from opiate treatment. A paucity of research examined the extent to which psychosocial or behavioural interventions support or replace conventional pharmacological approaches.
Economic evaluation provides a useful framework to assist policy makers in allocating resources across competing needs. Opiate dependence is a considerable burden on society’s resources, and treatment provides a cost-beneficial solution to address these consequences. However, to better inform the decision-making process, researchers must continue to produce high-quality, methodological, comparable and scientifically credible economic evaluations.
Literatur
1.
Zurück zum Zitat United Nations Office on Drags and Crime. World drag report. Vienna: UNODC, 2004 United Nations Office on Drags and Crime. World drag report. Vienna: UNODC, 2004
2.
Zurück zum Zitat Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 2002; 97 (11): 1383–1394PubMedCrossRef Darke S, Ross J. Suicide among heroin users: rates, risk factors and methods. Addiction 2002; 97 (11): 1383–1394PubMedCrossRef
3.
Zurück zum Zitat Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Dmg Alcohol Depend 1995; 40 (2): 139–150CrossRef Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Dmg Alcohol Depend 1995; 40 (2): 139–150CrossRef
4.
Zurück zum Zitat Hulse G, English DR, Milne E, et al. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94 (2): 221–229PubMedCrossRef Hulse G, English DR, Milne E, et al. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94 (2): 221–229PubMedCrossRef
5.
Zurück zum Zitat Hall W, Lynskey M, Degenhardt L. Heroin use in Australia [monograph 42]. Sydney: National Drag and Alcohol Research Centre, 1999 Hall W, Lynskey M, Degenhardt L. Heroin use in Australia [monograph 42]. Sydney: National Drag and Alcohol Research Centre, 1999
6.
Zurück zum Zitat European Monitoring Centre for Drags and Drag Addiction (EMCDDA). Annual report on the state of the drags problem in the European Union, 2001. Lisbon: EMCDDA, 2002 European Monitoring Centre for Drags and Drag Addiction (EMCDDA). Annual report on the state of the drags problem in the European Union, 2001. Lisbon: EMCDDA, 2002
7.
Zurück zum Zitat UN AIDS (Joint United Nations Programme on HIV/AIDS) and WHO (World Health Organization). AIDS epidemic update December 2001. Geneva: UNAIDS and WHO, 2002 UN AIDS (Joint United Nations Programme on HIV/AIDS) and WHO (World Health Organization). AIDS epidemic update December 2001. Geneva: UNAIDS and WHO, 2002
8.
Zurück zum Zitat World Health Organization. The world health report 2004. Geneva: WHO, 2004 World Health Organization. The world health report 2004. Geneva: WHO, 2004
9.
Zurück zum Zitat Single E, Robson L, Xie X, et al. The economic costs of alcohol, tobacco and illicit drags in Canada, 1992. Addiction 1998; 93 (7): 991–1006PubMedCrossRef Single E, Robson L, Xie X, et al. The economic costs of alcohol, tobacco and illicit drags in Canada, 1992. Addiction 1998; 93 (7): 991–1006PubMedCrossRef
10.
Zurück zum Zitat Collins DJ, Lapsley HM. Counting the cost: estimates of the social costs of drag abuse in Australia in 1998–99 [National Drag Strategy monograph series no. 49]. Canberra (ACT): Commonwealth of Australia, 2002 Collins DJ, Lapsley HM. Counting the cost: estimates of the social costs of drag abuse in Australia in 1998–99 [National Drag Strategy monograph series no. 49]. Canberra (ACT): Commonwealth of Australia, 2002
11.
Zurück zum Zitat Mark T, Woody GE, Juday T, et al. The economic costs of heroin addiction in the United States. Drag Alcohol Depend 2001; 61 (2): 195–206CrossRef Mark T, Woody GE, Juday T, et al. The economic costs of heroin addiction in the United States. Drag Alcohol Depend 2001; 61 (2): 195–206CrossRef
12.
Zurück zum Zitat García-Altés A, Ollé JM, Antoñanzas F, et al. The social cost of illegal drag consumption in Spain. Addiction 2002; 97 (9): 1145–1153PubMedCrossRef García-Altés A, Ollé JM, Antoñanzas F, et al. The social cost of illegal drag consumption in Spain. Addiction 2002; 97 (9): 1145–1153PubMedCrossRef
13.
Zurück zum Zitat Hammersley R, Forsyth A, Lavelle T. The criminality of new drag users in Glasgow. Br J Addict 1990; 85: 1583–1594PubMedCrossRef Hammersley R, Forsyth A, Lavelle T. The criminality of new drag users in Glasgow. Br J Addict 1990; 85: 1583–1594PubMedCrossRef
14.
Zurück zum Zitat Bell J, Hall W, Byth K. Changes in criminal activity after entering methadone maintenance. Br J Addict 1992; 87: 251–258PubMedCrossRef Bell J, Hall W, Byth K. Changes in criminal activity after entering methadone maintenance. Br J Addict 1992; 87: 251–258PubMedCrossRef
15.
Zurück zum Zitat Bell J, Mattick R, Hay A, et al. Methadone maintenance and drag-related crime. J Subst Abuse 1997; 9: 15–25PubMedCrossRef Bell J, Mattick R, Hay A, et al. Methadone maintenance and drag-related crime. J Subst Abuse 1997; 9: 15–25PubMedCrossRef
16.
Zurück zum Zitat Bennett T, Wright R. The impact of prescribing on the crimes of opioid users. Br J Addict 1986; 81: 265–273PubMedCrossRef Bennett T, Wright R. The impact of prescribing on the crimes of opioid users. Br J Addict 1986; 81: 265–273PubMedCrossRef
17.
Zurück zum Zitat Ball JC, Shaffer JW, Nurco DN. The day-to-day criminality of heroin addicts in Baltimore: a study in the continuity of offence rates. Drag Alcohol Depend 1983; 12 (2): 119–142CrossRef Ball JC, Shaffer JW, Nurco DN. The day-to-day criminality of heroin addicts in Baltimore: a study in the continuity of offence rates. Drag Alcohol Depend 1983; 12 (2): 119–142CrossRef
18.
Zurück zum Zitat Hubbard RL, Marsden ME, Rachal JV, et al. Drag abuse treatment: a national study of effectiveness. London: Chapel Hill, 1989 Hubbard RL, Marsden ME, Rachal JV, et al. Drag abuse treatment: a national study of effectiveness. London: Chapel Hill, 1989
19.
Zurück zum Zitat Rothbard A, Alterman A, Rutherford M, et al. Revisiting the effectiveness of methadone treatment on crime reductions in the 1990s. J Subst Abuse Treat 1999; 16 (4): 329–335PubMedCrossRef Rothbard A, Alterman A, Rutherford M, et al. Revisiting the effectiveness of methadone treatment on crime reductions in the 1990s. J Subst Abuse Treat 1999; 16 (4): 329–335PubMedCrossRef
20.
Zurück zum Zitat Gossop M, Marsden J, Stewart D, et al. Reductions in acquisitive crime and drag use after treatment of addiction problems: 1-year follow-up outcomes. Drag Alcohol Depend 2000; 58 (1-2): 165–172CrossRef Gossop M, Marsden J, Stewart D, et al. Reductions in acquisitive crime and drag use after treatment of addiction problems: 1-year follow-up outcomes. Drag Alcohol Depend 2000; 58 (1-2): 165–172CrossRef
21.
Zurück zum Zitat Gossop M, Trakada K, Stewart D, et al. Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drag Alcohol Depend 2005; 79 (3): 295–302CrossRef Gossop M, Trakada K, Stewart D, et al. Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drag Alcohol Depend 2005; 79 (3): 295–302CrossRef
22.
Zurück zum Zitat World Health Organization. WHO report on neuroscience of psychoactive substance use and dependence. Geneva: WHO, 2005 World Health Organization. WHO report on neuroscience of psychoactive substance use and dependence. Geneva: WHO, 2005
23.
Zurück zum Zitat Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2004 Oct 18; (4): CD005031 Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2004 Oct 18; (4): CD005031
24.
Zurück zum Zitat Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2004 Oct 18; (4): CD004147PubMed Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2004 Oct 18; (4): CD004147PubMed
25.
Zurück zum Zitat Clark N, Lintzeris N, Gijsbers A, et al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev 2002; (2): CD002210 Clark N, Lintzeris N, Gijsbers A, et al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev 2002; (2): CD002210
26.
Zurück zum Zitat Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 2002; (2): CD002021 Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 2002; (2): CD002021
27.
Zurück zum Zitat Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2002; (2): CD002025 Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2002; (2): CD002025
28.
Zurück zum Zitat Farrell M, Ward J, Mattick R, et al. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309 (6960): 997–1001PubMedCrossRef Farrell M, Ward J, Mattick R, et al. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309 (6960): 997–1001PubMedCrossRef
29.
Zurück zum Zitat National Institute on Drag Abuse. Report of the Blue Ribbon Task Force on Health Services Research at the National Institute on Drag Abuse. Washington, DC: National Institutes of Health, US Department of Health and Human Services, 2004 National Institute on Drag Abuse. Report of the Blue Ribbon Task Force on Health Services Research at the National Institute on Drag Abuse. Washington, DC: National Institutes of Health, US Department of Health and Human Services, 2004
30.
Zurück zum Zitat Tucker T, Ritter A. Naltrexone in the treatment of heroin dependence: a literature review. Drag and Alcohol Review 2000; 19: 73–82CrossRef Tucker T, Ritter A. Naltrexone in the treatment of heroin dependence: a literature review. Drag and Alcohol Review 2000; 19: 73–82CrossRef
31.
Zurück zum Zitat Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; (2): CD002207 Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; (2): CD002207
32.
Zurück zum Zitat Cartwright WS. Cost-benefit analysis of drag treatment services: review of the literature. J Ment Health Policy Econ 2000; 3: 11–26PubMedCrossRef Cartwright WS. Cost-benefit analysis of drag treatment services: review of the literature. J Ment Health Policy Econ 2000; 3: 11–26PubMedCrossRef
33.
Zurück zum Zitat French MT, Drammond MF. A research agenda for economic evaluation of substance abuse services. J Subst Abuse Treat 2005; 29: 125–137PubMedCrossRef French MT, Drammond MF. A research agenda for economic evaluation of substance abuse services. J Subst Abuse Treat 2005; 29: 125–137PubMedCrossRef
34.
Zurück zum Zitat Drammond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 2005 Drammond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 2005
35.
Zurück zum Zitat Gold M, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996 Gold M, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
36.
Zurück zum Zitat McCollister KE, French MT. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction 2003; 98: 1647–1659PubMedCrossRef McCollister KE, French MT. The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings. Addiction 2003; 98: 1647–1659PubMedCrossRef
37.
Zurück zum Zitat French M, Martin R. The costs of drug abuse consequences: a summary of research findings. J Subst Abuse Treat 1996; 13 (6): 453–466PubMedCrossRef French M, Martin R. The costs of drug abuse consequences: a summary of research findings. J Subst Abuse Treat 1996; 13 (6): 453–466PubMedCrossRef
38.
Zurück zum Zitat Choi B, Robson L, Single E. Estimating the economic costs of the abuse of tobacco, alcohol and illicit drugs: a review of methodologies and Canadian data sources. Chronic Dis Can 1997; 18 (4): 149–165PubMed Choi B, Robson L, Single E. Estimating the economic costs of the abuse of tobacco, alcohol and illicit drugs: a review of methodologies and Canadian data sources. Chronic Dis Can 1997; 18 (4): 149–165PubMed
39.
Zurück zum Zitat Hall W, Doran CM, Degenhardt L, et al. Illicit opioid use. In: Jamison D, Breman J, Measham JG, editors. Disease control priorities in developing countries. New York: Oxford University Press, 2006: 907–932 Hall W, Doran CM, Degenhardt L, et al. Illicit opioid use. In: Jamison D, Breman J, Measham JG, editors. Disease control priorities in developing countries. New York: Oxford University Press, 2006: 907–932
40.
Zurück zum Zitat Simoens S, Ludbrook A, Matheson C, et al. Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. Drug Alcohol Depend 2006; 84 (1): 28–39PubMedCrossRef Simoens S, Ludbrook A, Matheson C, et al. Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. Drug Alcohol Depend 2006; 84 (1): 28–39PubMedCrossRef
41.
Zurück zum Zitat Simoens S, Matheson C, Inkster K, et al. The effectiveness of treatment for drug users: an international systematic review of the evidence. Edinburgh: Scottish Executive Drug Misuse Research Programme, 2002 Simoens S, Matheson C, Inkster K, et al. The effectiveness of treatment for drug users: an international systematic review of the evidence. Edinburgh: Scottish Executive Drug Misuse Research Programme, 2002
42.
Zurück zum Zitat French M, McGeary K. Estimating the economic cost of substance abuse treatment. Health Econ 1997; 6: 1–6CrossRef French M, McGeary K. Estimating the economic cost of substance abuse treatment. Health Econ 1997; 6: 1–6CrossRef
43.
Zurück zum Zitat French M, Dunlap LJ, Zarkin GA, et al. A structured instrument for estimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat 1997; 14 (5): 445–455PubMedCrossRef French M, Dunlap LJ, Zarkin GA, et al. A structured instrument for estimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat 1997; 14 (5): 445–455PubMedCrossRef
44.
Zurück zum Zitat Bradley CJ, French MT, Rachal JV. Financing and cost of standard and enhanced methadone treatment. J Subst Abuse Treat 1994; 11 (5): 433–442PubMedCrossRef Bradley CJ, French MT, Rachal JV. Financing and cost of standard and enhanced methadone treatment. J Subst Abuse Treat 1994; 11 (5): 433–442PubMedCrossRef
45.
Zurück zum Zitat French MT, Bradley CJ, Calingaert B, et al. Cost analysis of training and employment services in methadone treatment. Eval Program Plann 1994; 17 (2): 107–120CrossRef French MT, Bradley CJ, Calingaert B, et al. Cost analysis of training and employment services in methadone treatment. Eval Program Plann 1994; 17 (2): 107–120CrossRef
46.
Zurück zum Zitat Roebuck C, French MT, McLellan T. DATS tats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat 2003; 25: 51–57PubMedCrossRef Roebuck C, French MT, McLellan T. DATS tats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program (DATCAP). J Subst Abuse Treat 2003; 25: 51–57PubMedCrossRef
47.
Zurück zum Zitat Alexandre PK, Roebuck MC, French MT, et al. The cost of residential addiction treatment in public housing. J Subst Abuse Treat 2003; 24 (4): 285–290PubMedCrossRef Alexandre PK, Roebuck MC, French MT, et al. The cost of residential addiction treatment in public housing. J Subst Abuse Treat 2003; 24 (4): 285–290PubMedCrossRef
48.
Zurück zum Zitat French MT, Salome HJ, Carney M. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington (provisional record). Soc Sci Med 2002; 55 (12): 2267–2282PubMedCrossRef French MT, Salome HJ, Carney M. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington (provisional record). Soc Sci Med 2002; 55 (12): 2267–2282PubMedCrossRef
49.
Zurück zum Zitat French MT, Salomé HJ, Krupski A, et al. Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington. Eval Rev 2000; 24 (6): 609–634PubMedCrossRef French MT, Salomé HJ, Krupski A, et al. Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington. Eval Rev 2000; 24 (6): 609–634PubMedCrossRef
50.
Zurück zum Zitat Salomé HJ, French MT, Miller M, et al. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (client DATCAP). Drug Alcohol Depend 2003; 71 (2): 195–206PubMedCrossRef Salomé HJ, French MT, Miller M, et al. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (client DATCAP). Drug Alcohol Depend 2003; 71 (2): 195–206PubMedCrossRef
51.
Zurück zum Zitat Mattick RP, Digiusto E, Doran CM, et al. National evaluation of pharmacotherapies for opioid dependence (NEPOD). Canberra: Commonwealth Department of Health and Ageing, 2001 Mattick RP, Digiusto E, Doran CM, et al. National evaluation of pharmacotherapies for opioid dependence (NEPOD). Canberra: Commonwealth Department of Health and Ageing, 2001
52.
Zurück zum Zitat Shanahan MD, Doran CM, Digiusto E, et al. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict Behav 2006; 31 (3): 371–387PubMedCrossRef Shanahan MD, Doran CM, Digiusto E, et al. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addict Behav 2006; 31 (3): 371–387PubMedCrossRef
53.
Zurück zum Zitat Shepard DS, Larson MJ, Hoffmann NG. Cost-effectiveness of substance abuse services: implications for public policy. Psychiatr Clin North Am 1999; 22 (2): 385–400PubMedCrossRef Shepard DS, Larson MJ, Hoffmann NG. Cost-effectiveness of substance abuse services: implications for public policy. Psychiatr Clin North Am 1999; 22 (2): 385–400PubMedCrossRef
54.
Zurück zum Zitat Gossop M, Strang J. Price, cost and value of opiate detoxification treatments: reanalysis of data from two randomised trials. Br J Psychiatry 2000; 177: 262–266PubMedCrossRef Gossop M, Strang J. Price, cost and value of opiate detoxification treatments: reanalysis of data from two randomised trials. Br J Psychiatry 2000; 177: 262–266PubMedCrossRef
55.
Zurück zum Zitat De Jong C, Laheij R, Krabbe P, et al. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction 2005; 100 (2): 206–215PubMedCrossRef De Jong C, Laheij R, Krabbe P, et al. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction 2005; 100 (2): 206–215PubMedCrossRef
56.
Zurück zum Zitat Doran CM, Shanahan M, Bell J, et al. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug Alcohol Rev 2004; 23 (2): 171–175PubMedCrossRef Doran CM, Shanahan M, Bell J, et al. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug Alcohol Rev 2004; 23 (2): 171–175PubMedCrossRef
57.
Zurück zum Zitat Hartz DT, Meek P, Piotrowski NA, et al. A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment. Am J Drug Alcohol Abuse 1999; 25 (2): 207–218PubMedCrossRef Hartz DT, Meek P, Piotrowski NA, et al. A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment. Am J Drug Alcohol Abuse 1999; 25 (2): 207–218PubMedCrossRef
58.
Zurück zum Zitat Masson C, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction 2004; 99 (6): 718–726PubMedCrossRef Masson C, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction 2004; 99 (6): 718–726PubMedCrossRef
59.
Zurück zum Zitat Doran CM, Shanahan M, Digiusto E, et al. A cost-effectiveness analysis of maintenance agonist treatments in the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Exp Rev Pharmacoeconomics Outcomes Res 2006; 6 (4): 437–446CrossRef Doran CM, Shanahan M, Digiusto E, et al. A cost-effectiveness analysis of maintenance agonist treatments in the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Exp Rev Pharmacoeconomics Outcomes Res 2006; 6 (4): 437–446CrossRef
60.
Zurück zum Zitat Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94 (4): 479–488PubMedCrossRef Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction 1999; 94 (4): 479–488PubMedCrossRef
61.
Zurück zum Zitat Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000; 90 (7): 1100–1111PubMedCrossRef Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000; 90 (7): 1100–1111PubMedCrossRef
62.
Zurück zum Zitat Strang J, Marsden J, Cummins M, et al. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction 2000; 95 (11): 1631–1645PubMedCrossRef Strang J, Marsden J, Cummins M, et al. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction 2000; 95 (11): 1631–1645PubMedCrossRef
63.
Zurück zum Zitat Kraft M, Rothbard AB, Hadley TR, et al. Are supplementary services provided during methadone maintenance really cost-effective? Am J Psychiatry 1997; 154 (9): 1214–1219PubMed Kraft M, Rothbard AB, Hadley TR, et al. Are supplementary services provided during methadone maintenance really cost-effective? Am J Psychiatry 1997; 154 (9): 1214–1219PubMed
64.
Zurück zum Zitat Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry 1999; 156 (1): 27–33PubMed Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry 1999; 156 (1): 27–33PubMed
65.
Zurück zum Zitat Sigmon SC, Stitzer ML. Use of low-cost incentive intervention to improve counseling attendance among methadone maintained patients. J Subst Abuse Treat 2005; 29 (4): 253–258PubMedCrossRef Sigmon SC, Stitzer ML. Use of low-cost incentive intervention to improve counseling attendance among methadone maintained patients. J Subst Abuse Treat 2005; 29 (4): 253–258PubMedCrossRef
66.
Zurück zum Zitat Warren E, Viney R, Shearer J, et al. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend 2006; 84 (2): 160–166PubMedCrossRef Warren E, Viney R, Shearer J, et al. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend 2006; 84 (2): 160–166PubMedCrossRef
67.
Zurück zum Zitat Dolan K, Shearer J, Macdonald M, et al. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 2003; 72: 59–65PubMedCrossRef Dolan K, Shearer J, Macdonald M, et al. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 2003; 72: 59–65PubMedCrossRef
68.
Zurück zum Zitat Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001; 96: 1267–1278PubMedCrossRef Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001; 96: 1267–1278PubMedCrossRef
69.
Zurück zum Zitat Doran CM, Shanahan M, Mattick RP, et al. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003; 71 (3): 295–302PubMedCrossRef Doran CM, Shanahan M, Mattick RP, et al. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 2003; 71 (3): 295–302PubMedCrossRef
70.
Zurück zum Zitat Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005; 23 (1): 77–91PubMedCrossRef Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics 2005; 23 (1): 77–91PubMedCrossRef
71.
Zurück zum Zitat Dijkgraaf MG, van der Zanden BP, de Borgie CA, et al. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005; 330 (7503): 1297–1302PubMedCrossRef Dijkgraaf MG, van der Zanden BP, de Borgie CA, et al. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005; 330 (7503): 1297–1302PubMedCrossRef
72.
Zurück zum Zitat Mojtabai R, Zivin JG. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis (provisional record). Health Serv Res 2003; 38 (1): 233–259PubMedCrossRef Mojtabai R, Zivin JG. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis (provisional record). Health Serv Res 2003; 38 (1): 233–259PubMedCrossRef
73.
Zurück zum Zitat Hubbard RL, Rachal JV, Craddock SG. Treatment Outcome Prospective Study (TOPS): client characteristics and behaviors before, during, and after treatment. In: Tims FM, Ludford JP, editors. Drug abuse treatment evaluation: strategies, progress, and prospects [National Institute on Drug Abuse Research monograph no. 51; DHHS publication no. (ADM) 84-1329]. Washington, DC: US Government Print Office, 1984 Hubbard RL, Rachal JV, Craddock SG. Treatment Outcome Prospective Study (TOPS): client characteristics and behaviors before, during, and after treatment. In: Tims FM, Ludford JP, editors. Drug abuse treatment evaluation: strategies, progress, and prospects [National Institute on Drug Abuse Research monograph no. 51; DHHS publication no. (ADM) 84-1329]. Washington, DC: US Government Print Office, 1984
74.
Zurück zum Zitat Mauser E, Van Stelle KR, Moberg DP. The economic impact of diverting substance-abusing offenders into treatment. Crime Delinq 1994; 40 (4): 568–588CrossRef Mauser E, Van Stelle KR, Moberg DP. The economic impact of diverting substance-abusing offenders into treatment. Crime Delinq 1994; 40 (4): 568–588CrossRef
75.
Zurück zum Zitat The California Dmg and Alcohol Treatment Assessment (CALDATA) general report. Sacramento (CA): State of California, Department of Alcohol and Drug Programs, 1994 The California Dmg and Alcohol Treatment Assessment (CALDATA) general report. Sacramento (CA): State of California, Department of Alcohol and Drug Programs, 1994
76.
Zurück zum Zitat Hser Y, Teruya E, Hardy M, et al. The California Treatment Outcome Project (CalTOP) final report submitted to the California Department of Alcohol and Drug Programs. Los Angeles (CA): UCLA Integrated Substance Abuse Programs, 2002 Hser Y, Teruya E, Hardy M, et al. The California Treatment Outcome Project (CalTOP) final report submitted to the California Department of Alcohol and Drug Programs. Los Angeles (CA): UCLA Integrated Substance Abuse Programs, 2002
77.
Zurück zum Zitat Gossop M, Marsden J, Stewart D, et al. Substance use, health and social problems of service users at 54 drug treatment agencies: intake data from the National Treatment Outcome Research Study. Br J Psychiatry 1998; 173: 166–171PubMedCrossRef Gossop M, Marsden J, Stewart D, et al. Substance use, health and social problems of service users at 54 drug treatment agencies: intake data from the National Treatment Outcome Research Study. Br J Psychiatry 1998; 173: 166–171PubMedCrossRef
78.
Zurück zum Zitat Harwood H, Hubbard RL, Collins JJ, et al. The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data, in compulsory treatment of drug abuse. Research and clinical practice. Rockville (MD): US Department of Health and Human Services, National Institutes of Health, 1998 Harwood H, Hubbard RL, Collins JJ, et al. The costs of crime and the benefits of drug abuse treatment: a cost-benefit analysis using TOPS data, in compulsory treatment of drug abuse. Research and clinical practice. Rockville (MD): US Department of Health and Human Services, National Institutes of Health, 1998
79.
Zurück zum Zitat Harwood HJ, Napolitano DM, Kristiansen PL, et al. Economic costs to society of alcohol and drug abuse and mental illness. Research Triangle Park (NC): Research Triangle Institute, 1984 Harwood HJ, Napolitano DM, Kristiansen PL, et al. Economic costs to society of alcohol and drug abuse and mental illness. Research Triangle Park (NC): Research Triangle Institute, 1984
80.
Zurück zum Zitat Rajkumar AS, French MT. Drug use, crime costs, and the economic benefits of treatment. J Quantitative Criminol 1997; 13: 291–323CrossRef Rajkumar AS, French MT. Drug use, crime costs, and the economic benefits of treatment. J Quantitative Criminol 1997; 13: 291–323CrossRef
81.
Zurück zum Zitat Gerstein DR, Johnson RA, Harwood H, et al. Evaluating recovery services: the California drug and alcohol treatment system (CALDATA). Sacramento (CA): California Department of Alcohol and Drug Programs, 1994 Gerstein DR, Johnson RA, Harwood H, et al. Evaluating recovery services: the California drug and alcohol treatment system (CALDATA). Sacramento (CA): California Department of Alcohol and Drug Programs, 1994
82.
Zurück zum Zitat Ettner SL, Huang DH, Rose D, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment “pay for itself”? Health Serv Res 2006; 41 (1): 192–213PubMedCrossRef Ettner SL, Huang DH, Rose D, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment “pay for itself”? Health Serv Res 2006; 41 (1): 192–213PubMedCrossRef
83.
Zurück zum Zitat Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of dmg misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004; 99 (6): 697–707PubMedCrossRef Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of dmg misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004; 99 (6): 697–707PubMedCrossRef
84.
Zurück zum Zitat Gossop M, Marsden J, Stewart D. NTORS at one year: changes in substance use, health and criminal behaviour one year after intake. London: Department of Health, 1998 Gossop M, Marsden J, Stewart D. NTORS at one year: changes in substance use, health and criminal behaviour one year after intake. London: Department of Health, 1998
85.
Zurück zum Zitat Gossop M, Marsden J, Stewart D, et al. The National Treatment Outcome Research Study in the United Kingdom: six month follow-up outcomes. Psychol Addict Behav 1997; 11: 324–337CrossRef Gossop M, Marsden J, Stewart D, et al. The National Treatment Outcome Research Study in the United Kingdom: six month follow-up outcomes. Psychol Addict Behav 1997; 11: 324–337CrossRef
86.
Zurück zum Zitat Gossop M, Marsden J, Stewart D, et al. Outcomes after methadone maintenance reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255–264PubMedCrossRef Gossop M, Marsden J, Stewart D, et al. Outcomes after methadone maintenance reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend 2001; 62: 255–264PubMedCrossRef
87.
Zurück zum Zitat French MT, Salome HJ, Carney M. Benefit-cost analysis of addiction treatment in Arkansas: specialty and standard residential programs for pregnant and parenting women. Soc Sci Med 2002; 55 (12): 2267–2282PubMedCrossRef French MT, Salome HJ, Carney M. Benefit-cost analysis of addiction treatment in Arkansas: specialty and standard residential programs for pregnant and parenting women. Soc Sci Med 2002; 55 (12): 2267–2282PubMedCrossRef
88.
Zurück zum Zitat Daley M, Argeriou M, McCarty D, et al. The costs of crime and the benefits of substance abuse treatment for pregnant women. J Subst Abuse Treat 2000; 19 (4): 445–458PubMedCrossRef Daley M, Argeriou M, McCarty D, et al. The costs of crime and the benefits of substance abuse treatment for pregnant women. J Subst Abuse Treat 2000; 19 (4): 445–458PubMedCrossRef
89.
Zurück zum Zitat Fals-Stewart W, Birchler GR, O’Farrell TJ. Behavioral couples therapy for male substance-abusing patients: effects on relationship adjustment and drug-using behavior J Consult Clin Psychol 1996; 64: 959–972PubMedCrossRef Fals-Stewart W, Birchler GR, O’Farrell TJ. Behavioral couples therapy for male substance-abusing patients: effects on relationship adjustment and drug-using behavior J Consult Clin Psychol 1996; 64: 959–972PubMedCrossRef
90.
Zurück zum Zitat Fals-Stewart W, O’Farrell TJ, Birchler GR. Behavioral couples therapy for male substance-abusing patients: a cost outcomes analysis. J Consult Clin Psychol 1997; 65: 789–802PubMedCrossRef Fals-Stewart W, O’Farrell TJ, Birchler GR. Behavioral couples therapy for male substance-abusing patients: a cost outcomes analysis. J Consult Clin Psychol 1997; 65: 789–802PubMedCrossRef
91.
Zurück zum Zitat Koenig L, Siegel JM, Harwood H, et al. Economic benefits of substance abuse treatment: findings from Cuyahoga County, Ohio. J Subst Abuse Treat 2005; 28: S41–S50PubMedCrossRef Koenig L, Siegel JM, Harwood H, et al. Economic benefits of substance abuse treatment: findings from Cuyahoga County, Ohio. J Subst Abuse Treat 2005; 28: S41–S50PubMedCrossRef
Metadaten
Titel
Economic Evaluation of Interventions to Treat Opiate Dependence
A Review of the Evidence
verfasst von
Dr Christopher M. Doran
Publikationsdatum
01.05.2008
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 5/2008
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200826050-00003

Weitere Artikel der Ausgabe 5/2008

PharmacoEconomics 5/2008 Zur Ausgabe